Zynex PE Ratio 2006-2018 | ZYXI
Current and historical p/e ratio for Zynex (ZYXI) from 2006 to 2018. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Zynex PE ratio as of March 22, 2019 is 15.52.
| Zynex PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2019-03-22 | 4.50 | inf | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.145B | $0.032B |
| Zynex, Inc. engineers, manufactures, markets, and sells medical devices for the electrotherapy, and stroke and spinal cord injury rehabilitation markets primarily in the United States. The company primarily offers electrotherapy products for pain relief and pain management; and NeuroMove for stroke and spinal cord injury rehabilitation. The company's product lines are fully developed, FDA-cleared, commercially sold, and have been developed to uphold the Company's mission of improving the quality of life for patients suffering from impaired mobility due to stroke, spinal cord injury, or debilitating and chronic pain. Zynex markets its products through commissioned and independent sales representatives, as well as directly to end users through advertisements and articles in relevant publications and on the Internet. The company is headquartered in Littleton, Colorado. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $136.952B | 27.07 |
| Medtronic (MDT) | Ireland | $121.227B | 17.72 |
| Stryker (SYK) | United States | $72.547B | 26.60 |
| Boston Scientific (BSX) | United States | $51.696B | 25.20 |
| Baxter (BAX) | United States | $39.588B | 25.32 |
| Zimmer Biomet Holdings (ZBH) | United States | $25.898B | 16.58 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $17.446B | 0.00 |
| Canopy Growth (CGC) | Canada | $14.852B | 0.00 |
| ResMed (RMD) | United States | $14.350B | 27.21 |
| Bio-Rad Laboratories (BIO) | United States | $9.156B | 52.24 |
| Aurora Cannabis (ACB) | Canada | $9.141B | 64.50 |
| Hill-Rom Holdings (HRC) | United States | $6.962B | 21.53 |
| Perrigo (PRGO) | Ireland | $6.420B | 10.41 |
| Insulet (PODD) | United States | $5.800B | 1956.80 |
| GW Pharmaceuticals (GWPH) | United Kingdom | $5.092B | 0.00 |
| ICU Medical (ICUI) | United States | $4.698B | 29.24 |
| Haemonetics (HAE) | United States | $4.311B | 38.24 |
| Hutchison China MediTech (HCM) | China | $3.810B | 0.00 |
| Agios Pharmaceuticals (AGIO) | United States | $3.637B | 0.00 |
| Neogen (NEOG) | United States | $3.108B | 47.74 |
| NuVasive (NUVA) | United States | $2.892B | 25.23 |
| Quidel (QDEL) | United States | $2.514B | 22.68 |
| Aphria (APHA) | $2.385B | 105.89 | |
| National Vision Holdings (EYE) | United States | $2.274B | 44.72 |
| Cardiovascular Systems (CSII) | United States | $1.346B | 966.50 |
| HEXO (HEXO) | $1.340B | 0.00 | |
| Phibro Animal Health (PAHC) | United States | $1.283B | 18.45 |
| VAREX IMAGING (VREX) | United States | $1.275B | 24.96 |
| AtriCure (ATRC) | United States | $1.081B | 0.00 |
| MacroGenics (MGNX) | United States | $0.926B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $0.911B | 24.60 |
| Cerus (CERS) | United States | $0.844B | 0.00 |
| PetIQ (PETQ) | United States | $0.831B | 23.77 |
| Omeros (OMER) | United States | $0.828B | 0.00 |
| NanoString Technologies (NSTG) | United States | $0.729B | 0.00 |
| Meridian Bioscience (VIVO) | United States | $0.715B | 21.30 |
| OraSure Technologies (OSUR) | United States | $0.664B | 29.11 |
| Eagle Pharmaceuticals (EGRX) | United States | $0.657B | 22.35 |
| Evolus (EOLS) | United States | $0.655B | 0.00 |
| TG Therapeutics (TGTX) | United States | $0.601B | 0.00 |
| LeMaitre Vascular (LMAT) | United States | $0.596B | 28.35 |
| Surmodics (SRDX) | United States | $0.563B | 81.90 |
| Quanterix (QTRX) | United States | $0.518B | 0.00 |
| BioLife Solutions (BLFS) | United States | $0.364B | 150.23 |
| Vapotherm (VAPO) | United States | $0.335B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.331B | 0.00 |
| Insys Therapeutics (INSY) | United States | $0.328B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.300B | 19.49 |
| Owens & Minor (OMI) | United States | $0.271B | 3.76 |
| Bovie Medical (APYX) | United States | $0.260B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.241B | 0.00 |
| Neptune Technologies & Bioresources Inc (NEPT) | Canada | $0.238B | 0.00 |
| Fonar (FONR) | United States | $0.137B | 7.33 |
| Surface Oncology (SURF) | United States | $0.116B | 0.00 |
| Chimerix (CMRX) | United States | $0.102B | 0.00 |
| Female Health (VERU) | United States | $0.100B | 0.00 |
| Chembio Diagnostics (CEMI) | United States | $0.096B | 0.00 |
| InfuSystems Holdings (INFU) | United States | $0.091B | 0.00 |
| United-Guardian (UG) | United States | $0.087B | 19.84 |
| CAS Medical Systems (CASM) | United States | $0.072B | 0.00 |
| Neurotrope (NTRP) | United States | $0.065B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.058B | 17.14 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.056B | 0.00 |
| Conatus Pharmaceuticals (CNAT) | United States | $0.039B | 0.00 |
| ImmuCell (ICCC) | United States | $0.038B | 0.00 |
| Valeritas Holdings (VLRX) | United States | $0.035B | 0.00 |
| Senestech (SNES) | United States | $0.029B | 0.00 |
| Myomo (MYO) | United States | $0.022B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.018B | 0.00 |
| InVivo Therapeutics Holdings (NVIV) | United States | $0.016B | 0.00 |
| Akers Biosciences Inc (AKER) | United States | $0.013B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.011B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.008B | 15.29 |
